Aiman Shalabi BS, MBA, PharmD, BCOP

Aiman Shalabi is a global executive with over 20 years’ experience in driving new treatments for patients with cancer. Aiman’s key strength is aligning multiple stakeholders in areas of complex science to develop a common vision and execute against that vision. He is currently the chief medical officer at the Cancer Research Institute (CRI) where he provides strategic direction and integrated oversight for CRI’s cancer immunotherapy clinical trial program, the Clinical Accelerator.

Previously, Aiman was the vice president, Global Medical Affairs group for Immune Oncology at AstraZeneca and was also the global product vice president at AstraZeneca leading the cross-functional development team for PD-L1. He also led multiple immuno-oncology programs at MedImmune including an accelerated PD-L1 program from first-in-human to phase III start in 14 months, supported the in-licensing and initiated development of tremelimumab and OX40 and initiated the IO combination studies early in the development cycle. He also served as the chair of the Joint Steering Committee and implemented novel external collaborations with the Cancer Research Institute, Friends of Cancer Research, SWOG, NCIC (Canada), and the National Cancer Institute